Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice

Clinical Cancer Research

Volumn 6, Issue 12, 2000, Pages 4893-4899

  Lee, Eun Sook ^a   Schafer, Jennifer Macgregor ^a   England, Gale ^a   O’Regan, Ruth M ^a   Reyes, Alexander De Los ^a   Craig Jordan, V ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1,2 TRIPHENYLETHYLENE DERIVATIVE; ANTIESTROGEN; ESTRADIOL; IDOXIFENE; TAMOXIFEN; TOREMIFENE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CONTROLLED STUDY; CROSS RESISTANCE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TREATMENT FAILURE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; STILBENES; TAMOXIFEN; TIME FACTORS; TOREMIFENE; TUMOR CELLS, CULTURED;

EID: 0034490211     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Tamoxifen for early breast cancer: An overview of the randomised trials
2. Tamoxifen in the treatment of breast cancer
3. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
4. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
5. Clinical potential of new antiestrogens
6. Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent
7. Metabolism of the 4-iodo derivative of tamoxifen by isolated rat hepatocytes. Demonstration that the iodine atom reduces metabolic conversion and identification of four metabolites
8. Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer
9. Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts
10. The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance
11. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis
12. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer
13. Toxicity and early survival results of a prospective, randomized adjuvant trial comparing toremifene and tamoxifen in node-positive breast cancer
14. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats
15. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells
16. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration
17. Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice
18. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice
19. Rapid development of tamoxifen stimulated mutant p53 breast tumors (T47D) in athymic mice
20. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer
21. Pharmaco-kinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer
22. Antiestrogenic action of toremifene on hormone-dependent, -independent and heterogeneous breast tumor growth in the athymic mouse
23. Effects of the antiestrogens tamoxifen, toremifene and ICI 182,780 on endometrial cancer growth
24. Mechanisms for tamoxifen resistance in breast cancer: Possible role of tamoxifen metabolism
25. The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer
26. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen
27. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients
28. Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors
29. Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen
30. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer
31. Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts
32. Idoxifene: Report of a Phase I study in patients with metastatic breast cancer
33. Molecular mechanism of action of raloxifene and tamoxifen: Today and tomorrow
34. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes
35. Toremifene and tamoxifen in advanced breast cancer - A double-blind cross-over trial
36. Multicenter Phase II efficacy trial of toremifene in tamoxifen - Refractory patients with advanced breast cancer
37. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients